Clinical Trials Logo

Glucose Metabolism clinical trials

View clinical trials related to Glucose Metabolism.

Filter by:

NCT ID: NCT03648112 Completed - Satiety Clinical Trials

Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety

gLUCAn
Start date: May 2, 2018
Phase: N/A
Study type: Interventional

The interventional study will evaluate the effects of a regularly consumption of barley and oat flakes in crude and roasted form on the glucose and lipid metabolism as well as the postprandial saturation. Moreover, the study will evaluate the effect of a regularly consumption of barley and oat flakes on the glucose and lipid metabolism over a period of three weeks. All participants will run through each intervention (cross-over design). Inbetween these intervention periods there will be wash-out phases. In total there will be four interventions: crude oat flakes, roasted oat flakes, crude barley flakes and roasted barley flakes. The comparison will be made against white toastbread. The study participants will visit the study centrum before and after each intervention over an entire period of 27 weeks.

NCT ID: NCT03627637 Completed - Clinical trials for Cognitive Performance

Soy and Brain Vascular Function

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

Cognitive performance is negatively related to an impaired glucose metabolism, possibly due to impairments in brain vascular function. Supported by the statement from the American Heart and American Stroke Association that healthy plant-based diets, which consist of soy foods, protect against cognitive decline, we now hypothesize that soy-induced changes in glucose metabolism cause beneficial effects on brain vascular function thereby improving cognitive performance. The primary objective of this intervention study is thus to evaluate in elderly men and women the effect of a 16-week soy intervention on cerebral blood flow, as quantified by the non-invasive gold standard magnetic resonance imaging (MRI) perfusion method Arterial Spin Labeling (ASL). Cerebral blood flow is a robust and sensitive physiological marker of brain vascular function. Secondary objectives are to examine effects on glucose metabolism using the oral glucose tolerance test and cognitive performance as assessed with a neurophysiological test battery.

NCT ID: NCT03272061 Completed - Clinical trials for Cognitive Performance

Exercise and Brain Vascular Function

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

Cognitive performance is negatively related to an impaired glucose metabolism, possibly due to impairments in brain vascular function. Supported by the statement from the American Heart and Stroke Association that physical exercise is one of the most effective strategies to protect against cognitive decline, we now hypothesize that exercise-induced changes in glucose metabolism cause beneficial effects on brain vascular function thereby improving cognitive performance. The primary objective of this intervention study is thus to evaluate in sedentary elderly men the effect of a 8-week aerobic-based exercise program on cerebral blood flow, as quantified by the non-invasive gold standard magnetic resonance imaging (MRI) perfusion method Arterial Spin Labeling (ASL). Cerebral blood flow is a robust and sensitive physiological marker of brain vascular function. Secondary objectives are to examine effects on glucose metabolism using the oral glucose tolerance test and cognitive performance as assessed with a neurophysiological test battery.

NCT ID: NCT02854709 Completed - Glucose Metabolism Clinical Trials

Effects of Sleep Extension on Glucose Metabolism in Chronically Sleep Deprived Individuals

Start date: July 2016
Phase: N/A
Study type: Interventional

This is a randomized cross over study of the effect of 2-week sleep extension in chronically sleep deprived non-diabetic individuals on glucose metabolism.

NCT ID: NCT02747472 Completed - Glucose Metabolism Clinical Trials

GIP Receptor Antagonist Studies in Humans

GA-1
Start date: April 2016
Phase: N/A
Study type: Interventional

Antagonizing GIP effects during hyperglycaemia in healthy subjects and measurements of insulin secretion.

NCT ID: NCT01877460 Completed - Health Clinical Trials

Sodium Alginate in Chocolate Milk, Satiety and Glycemic Control

Start date: January 2012
Phase: N/A
Study type: Interventional

This study compares the effects of isovolumetric (325 ml) preloads of chocolate milk supplemented with sodium alginates at incremental doses on inter-meal glucose levels, appetite scores and food intake in healthy adult men. The findings of this study will illustrate whether the addition of sodium alginate to chocolate milk will improve the glycemic properties of chocolate milk and will potentiate its satiating characteristics. This study will also elucidate whether sodium alginates, incorporated into chocolate milk, will influence glycemia, appetite sensations and food intake in a dose-dependent manner. It is hypothesized that there will be a synergy between milk and sodium alginate beyond either alone. When combined with milk components, sodium alginate is expected to improve glycemia and induce satiety more than does either milk alone or alginate alone.

NCT ID: NCT01801540 Completed - Glucose Metabolism Clinical Trials

The Effects of L-arabinose in a Meal in Healthy Men

Start date: December 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the effect of a meal containing different doses of L-arabinose, on the intestinal sucrase activity after intake We measure this by measuring the glucose, insulin and c-peptide after meals. Other measurements are made (glucagon and GLP-1) to explain the correlations.

NCT ID: NCT01686815 Completed - Schizophrenia Clinical Trials

Cross-Sectional Iloperidone IVGTT

Start date: October 2012
Phase:
Study type: Observational

This study aims to utilize state of the art procedures such as the frequently sampled intravenous glucose tolerance test (FSIVGTT), Bergman's Minimal Model Analysis, lipoprotein analysis, and DEXA scans to demonstrate that a newer agent, iloperidone, is devoid of the metabolic abnormalities associated with other atypical antipsychotic treatments, namely olanzapine and risperidone, and offers an advantage over these other agents.

NCT ID: NCT01673321 Completed - Healthy Clinical Trials

Protein Concentrations in Yogurt and Satiety, Food Intake and Glycemia in Healthy Men

Start date: February 2012
Phase: N/A
Study type: Interventional

This study compared the effects of dairy products, including milk and yogurt, with different amounts of proteins on responses of appetite, glucose and insulin and on food intake at a meal served 120 minutes later in healthy adult male individuals.

NCT ID: NCT01293422 Completed - Glucose Metabolism Clinical Trials

Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis

Rifa-2
Start date: January 2011
Phase: Phase 4
Study type: Interventional

This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.